Jim Simons
VBIO

Jim Simons’s Valion Bio VBIO Stock Holding History

Jim Simons’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,035
Closed -$4.39K – 3910
2024
Q3 		$4.39K Buy
+1,035
New +$6.25K ﹤0.01% 3479
2023
Q1 		– Sell
-15
Closed -$17K – 4401
2022
Q4 		$17K Buy
+15
New +$33.7K ﹤0.01% 3987
2022
Q3 		– Sell
-22
Closed -$73K – 4408
2022
Q2 		$73K Sell
22
-50
-69% -$147K ﹤0.01% 3925
2022
Q1 		$197K Buy
+72
New +$235K ﹤0.01% 3654

Other funds holding VBIO

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jim Simons's VBIO Position: Q4 2024 in Review

Jim Simons sold out of Valion Bio (VBIO) in Q4 2024, closing a stake of 1,035 shares — an estimated $4.39K sold.

Jim Simons first reported a position in VBIO in Q1 2022 and held it in 4 quarters. The position peaked at $197K in Q1 2022. 9 funds tracked by Wall St. Rank hold VBIO as of Q4 2024.

  • Jim Simons reported no remaining Valion Bio position as of Q4 2024 after selling out during the quarter.
  • Jim Simons sold 1,035 Valion Bio shares in Q4 2024, an estimated $4.39K.
  • Jim Simons first reported a position in Valion Bio in Q1 2022 and held it in 4 quarters.
  • Jim Simons's Valion Bio position peaked at $197K in Q1 2022.
  • 9 funds tracked by Wall St. Rank held Valion Bio as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.